Search
                    Polycystic Ovary Syndrome Clinical Trials
A listing of 27  Polycystic Ovary Syndrome  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 27
        
                There are currently 27 active clinical trials seeking participants for Polycystic Ovary Syndrome research studies. The states with the highest number of trials for Polycystic Ovary Syndrome participants are Virginia, Pennsylvania, Heilongjiang and California.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
                                
            
            
        Recruiting
                            
            
                Background:
Brown adipose tissue (BAT) is a type of fat in the body. It may prevent weight gain, improve insulin sensitivity, and reduce fatty liver. Researchers want to see if BAT helps the body burn energy.
Objective:
To learn more about how BAT works to burn energy.
Eligibility:
People ages 18-40 with a body mass index between 18 and 40
Design:
Participants will be screened with:
Medical history
Physical exam
Blood, urine, and heart tests
Dietitian interview
Participants will have...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 40 years
            Trial Updated:
                08/21/2025
            
            Locations: National Institutes of Health Clinical Center, Bethesda, Maryland         
        
        
            Conditions: Polycystic Ovary Syndrome
        
            
        
    
                
                                    The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
                                
            
            
        Recruiting
                            
            
                A Prospective, Multicenter, Randomized, Pivotal Study of the May Health System in Transvaginal Ablation of Ovarian Tissue under Ultrasound Guidance in Women with Infertility due to Polycystic Ovary Syndrome             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 40 years
            Trial Updated:
                08/04/2025
            
            Locations: UCSF Center for Reproductive Health, San Francisco, California  +15 locations         
        
        
            Conditions: Polycystic Ovary Syndrome, Infertility, Female
        
            
        
    
                
                                    Hyperandrogenemia and Altered Day-night LH Pulse Patterns
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone pulse frequency (primary endpoint).             
        
        
    Gender:
                FEMALE
            Ages:
                Between 10 years and 17 years
            Trial Updated:
                07/30/2025
            
            Locations: University of Virginia Clinical Research Unit, Charlottesville, Virginia         
        
        
            Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
        
            
        
    
                
                                    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine if estradiol augmentation of luteinizing hormone (LH) secretion secretion (primary endpoint) and follicle-stimulating hormone (FSH) secretion (secondary endpoint) is reduced in adult women with polycystic ovary syndrome.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 30 years
            Trial Updated:
                07/30/2025
            
            Locations: University of Virginia Clinical Research Unit, Charlottesville, Virginia         
        
        
            Conditions: Polycystic Ovary Syndrome
        
            
        
    
                
                                    Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism (HA), androgen-receptor blockade (spironolactone) alone normalizes sleep-wake luteinizing hormone (LH) pulse frequency (primary endpoint) and overall LH and follicle-stimulating hormone secretion (secondary endpoints).             
        
        
    Gender:
                FEMALE
            Ages:
                Between 10 years and 17 years
            Trial Updated:
                07/30/2025
            
            Locations: Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia         
        
        
            Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
        
            
        
    
                
                                    Dampening the Reproductive Axis With Continuous Kisspeptin
                                
            
            
        Recruiting
                            
            
                The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 45 years
            Trial Updated:
                07/22/2025
            
            Locations: Massachusetts General Hospital, Boston, Massachusetts         
        
        
            Conditions: Reproductive Disorder, PCOS, Polycystic Ovary Syndrome
        
            
        
    
                
                                    Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
                                
            
            
        Recruiting
                            
            
                Developed nations worldwide are currently enduring a health crisis, as chronic diseases continue to decrease quality of life and promote additional disease states or even death for much of the population. Rural populations are at a particular disadvantage, as they lack access to health clubs, wellness programs and similar resources that are more available in urban areas. Although pharmaceutical therapies have continued to show therapeutic advancements, the rates of disease onset and death from c...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 64 years
            Trial Updated:
                07/21/2025
            
            Locations: West Virginia School of Osteopathic Medicine, Lewisburg, West Virginia         
        
        
            Conditions: Obesity, Hyperlipidemias, Polycystic Ovary Syndrome, Hypertension, Coronary Heart Disease, Heart Failure, Depression, Anxiety, Type II Diabetes, Metabolic Syndrome
        
            
        
    
                
                                    Combined Oral Contraceptive Pill and Resistance Starch
                                
            
            
        Recruiting
                            
            
                This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 40 years
            Trial Updated:
                06/11/2025
            
            Locations: University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Metabolic Syndrome, Polycystic Ovary Syndrome
        
            
        
    
                
                                    Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/obese Women with PCOS
                                
            
            
        Recruiting
                            
            
                A prospective study to determine the metabolic effects of the contraceptive vaginal ring among overweight and obese women with polycystic ovary syndrome (PCOS). We will recruit a total of 40 participants and study use of the vaginal ring over a 4-month period.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 40 years
            Trial Updated:
                12/03/2024
            
            Locations: University of Pennsylvania, Philadelphia, Pennsylvania         
        
        
            Conditions: Polycystic Ovary Syndrome
        
            
        
    
                
                                    Inositol Supplementation to Treat PCOS (INSUPP-PCOS)
                                
            
            
        Recruiting
                            
            
                To determine if Inositol, a dietary supplement, will improve ovarian and adrenal androgen excess in women with Polycystic Ovarian Syndrome(PCOS).             
        
        
    Gender:
                FEMALE
            Ages:
                Between 18 years and 45 years
            Trial Updated:
                12/03/2024
            
            Locations: Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania  +1 locations         
        
        
            Conditions: Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
        
            
        
    
                
                                    Myo-Inositol for Infertility in PCOS
                                
            
            
        Recruiting
                            
            
                This will be a prospective, double-blind randomized clinical trial of letrozole and placebo versus letrozole and inositols for up to 5 treatment cycles of ovulation induction or until pregnancy is achieved. All participants and members of the research team will be blinded to the treatment arms. Placebo and inositol supplement will be packaged to appear the same, tested, and packaged by a commercial supply company. The inositols will be a 40:1 blend of myo-inositol and D-chiro inositol.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 36 years
            Trial Updated:
                09/13/2024
            
            Locations: OUHSC Reproductive Medicine Clinic, Oklahoma City, Oklahoma         
        
        
            Conditions: Polycystic Ovary Syndrome
        
            
        
    
                
                                    Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
                                
            
            
        Recruiting
                            
            
                The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, BMI, and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditi...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                09/05/2024
            
            Locations: Lilli Health, Houston, Texas         
        
        
            Conditions: Insulin Resistance, Polycystic Ovary Syndrome, Hyperinsulinism, Obesity, Metabolic Syndrome
        
            
        
    1 - 12 of 27
            